3-11-2021As the 2021 virtual Conference on Retroviruses and Opportunistic Infections (CROI) concluded, NIH’s Dr. Carl Dieffenbach joined HIV.gov for a conversation abo…
2-3-2021The HHS Substance Abuse and Mental Health Services Administration (SAMHSA) has released Prevention and Treatment of HIV Among People Living with Substance Use a…
1-22-2021@US_FDA has approved Cabenuva (cabotegravir and rilpivirine), the first injectable, complete treatment regimen for people with #HIV that is administered once a …
12-3-2020Cross-posted from NIAID NewsroomGrant Awards Set Stage for Next Seven Years of Science-Driven HIV Clinical ResearchThe National Institute of Allergy and Infec…
10-19-2020As one of several Indian Health Service activities supported by the Minority HIV/AIDS Fund (MHAF) in Fiscal Year 2020, the Urban Indian Health Institute (UIHI) …
9-16-2020The Centers for Disease Control and Prevention (CDC) is rolling out a new suite of HIV Treatment Works (HTW) products and materials as part of its Let’s Stop …
9-14-2020Cross-posted from the Office of AIDS ResearchThe NIH Office of AIDS Research (OAR) is pleased to announce the transition of the public AIDSinfo.nih.gov and inf…
8-24-2020The promise of long-acting injectable formulations of HIV medications to maintain viral load suppression is closer to reality, according to Constance A. Benson,…
7-21-2020Cross-posted from NIAID NewsroomThe National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and IAVI, a nonprofit scie…
7-14-2020Cross-posted from U.S. Food and Drug Administration[On July 2, 2020], the U.S. Food and Drug Administration approved Rukobia (fostemsavir), a new type of antire…
